NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB
The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tuesday 14 May...
Acarix announces the initiation of the first US-based clinical workflow evaluation study
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to colle...
Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review
Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based ...
New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (...
Acarix has submitted application for cross-trading at OTCQB in the US
New York, New York, April 5, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics announces the submission of a...
Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)
The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of seri...
Acarix receives declarations of intent to exercise warrants of series TO 2
Acarix AB ("Acarix" or the "Company") has received oral declarations of intent to exercise Warrants of series TO 2 (the "Warrants") fro...
CEO purchases shares in Acarix
New York, New York, March 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Aamir Mahmoo...
The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today
The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acarix" or the "Com...
Announcement from Acarix’s extra general meeting
The extra general meeting of Acarix AB (the "Company") was held today on 21 February 2024 and the following resolution was passed by th...
Acarix strengthens US Advisory Board with three industry leaders
New York, New York, February 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointmen...
Acarix AB (publ) publishes Year-End Report 2023
Embarking on a new journey with focus on sustainable growthAs the newly appointed CEO of Acarix, I am honored to be on board and share ...